David E. I. Pyott - 18 May 2023 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Reporting relationship: Director
Issuer ticker: ALNY
Reported as of: 18 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2023, 16:06:50 UTC
Prior SEC filing: 27 Feb 2023
Next SEC filing: 24 May 2023
Source filing: View source filing
Reporting owner signature: By: /s/ Stephen Hall, Attorney-in-Fact For: David E.I. Pyott

Key filing fact

David E. I. Pyott filed Form 4 for ALNYLAM PHARMACEUTICALS, INC. (ALNY) on 19 May 2023.

Key facts

This page summarizes David E. I. Pyott's Form 4 filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 May 2023, 16:06.

Change

Previous filing in this sequence was filed on 27 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALNY transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +3,454
Change %
Price: $0.000000
Shares after: 3,454
Date: 18 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,454
Exercise price: $189.87
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.